As the underlying genetic basis of hypertrophic cardiomyopathy is being characterized, there has been increasing recognition of the wide spectrum and variable evolution of this disease within the pediatric age range. This review outlines recent evidence relevant to the diagnosis, management, and prognosis of hypertrophic cardiomyopathy specific to children and adolescents. Recent findings Studies of putative causal genes are leading to the discovery of factors affecting the variability of phenotypic expression and possible avenues for new therapies. Nonetheless, the use of genetic testing currently remains for research purposes only. Echocardiography is the primary means for evaluation, with an increasing focus on diastolic performance. Useful prognostic information can be obtained from the safe performance of cardiopulmonary stress testing. Sudden death can occur in children, although the risk factors are likely different than in adults. The role and mechanisms for possible ischemia remain controversial, and likely differ between individuals. Activity restrictions are recommended, with medical therapy reserved for those who are symptomatic. For those with important left ventricular outflow obstruction, surgical myectomy may be indicated, with little current role for alcohol septal ablation. Advances in implantable defibrillators now make this therapy feasible in younger children. Summary There are important differences from adults in the approach to the diagnosis and management of hypertrophic cardiomyopathy in children and adolescents. Care regarding prognostication and therapy must be taken given the potential life-long implications.
Introduction
Hypertrophic cardiomyopathy (HCM) is a genetic disorder marked by primary myocardial hypertrophy without an identifiable cause. While previously thought to be a rare disorder, HCM is now thought to occur with an incidence of 1 in 500 in the general population and remains the most common cause of sudden death in children and young adults less than age 35 years [1] . Early literature, limited to patients from a few tertiary care centers, had documented an annual mortality rate of 6% in children and adolescents with HCM. More recent data from a larger cohort of patients suggests a less malignant disease course with an annual overall mortality rate of 1% [2 • ]. Despite important medical advances in the past several years, HCM in children remains a diagnostic and therapeutic challenge for the cardiologist.
Diagnosis Genetic evaluation
Since the first description of the genetic basis of HCM in 1989, major advances in genetic testing have occurred such that the genetically heterogeneous basis of HCM is well documented, with identification of at least 10 causative genes and over 150 identified mutations [3 • ]. Most of these mutations have been shown to be missense mutations with a single amino acid substitution within or close to important functional domains [4] . The involved genes encode sarcomere proteins, and thus affect the major contractile unit of the myocardium. Three genetic defects account for most cases of HCM, and include the beta MHC, myosin-binding protein C, and troponin T genes. While greater than 90% of patients with a beta MHC gene defect will demonstrate left ventricular hypertrophy in childhood, HCM secondary to mutations in one of the other genes may remain quiescent until adulthood [3 • ].
While earlier work identified the 10 causal genes, recent investigation has been directed toward identifying clinical correlates of specific intragenic mutations. The Toronto group recently identified nonconservative missense mutations within the beta MHC gene that are associated with an important decrease in survival when compared with conservative mutations involving the same gene [5 • ].
Unfortunately, genetic testing remains expensive, is confined to only a few research laboratories and, thus, is not universally available to most cardiologists treating children. In addition, published data from several centers indicate that mutations in sarcomeric protein genes account for only 60% of HCM cases [4] . Even for those with an identified genetic mutation, there exists variable interfamilial and intrafamilial clinical expression for individuals with identical mutations [6] . Phenotypic expression of HCM is thought to be the production not only of the causal mutation, but also of modifier genes and environmental factors [ 
Clinical evaluation Echocardiography
Two-dimensional echocardiography remains the primary diagnostic modality for identifying children with HCM. While previous recommendations involved intermittent echocardiographic assessments before age 18 years in those with a positive family history of HCM, it is now recognized that late onset may occur. Current recommendations for first degree relatives of affected family members include annual echocardiographic assessment in children ages 12 to 18 years and ongoing evaluation thereafter at intervals of every 5 years [7 •• ] . Evaluation of children younger than age 12 years should be dictated by family history and clinical assessment. Affected children and young adults are to be observed at least annually.
In addition to the echocardiographic evaluation of chamber dimensions and the assessment of resting and provocable left ventricular outflow tract obstruction, assessment of diastolic performance is important. Diastolic abnormalities have been shown to be frequent in children with HCM, and due to the abnormalities in both the active component of the dissociation of actin and myosin in the early filling phase and the passive properties of the ventricle that affect compliance [4] . Diastolic dysfunction has been shown to be the primary cause of exercise intolerance in these patients [ 
Risk stratification
The primary goal in the treatment of children and adolescents with HCM is alleviation of patient symptoms and the prevention of sudden death. Risk stratification plays an important role in directing patient treatment. The highest risk for sudden cardiac death has been associated with the presence of any of the following: previous cardiac arrest or spontaneously occurring sustained ventricular tachycardia [ 
Management Activity restrictions
Physical activity restrictions remain of paramount importance for children and adolescents with HCM. An increase in catecholamine levels may precipitate both an increase in left ventricular outflow tract obstruction and myocardial ischemia. The latest American Heart Association statement on exercise guidelines for children with genetic cardiovascular diseases continues to advise that young patients with HCM refrain from competitive athletics and isometric activities [18 • ].
Medical
Medical management is reserved for those patients who are symptomatic. It remains controversial as to whether asymptomatic children with marked resting left ventricular outflow tract obstruction (systolic pressure gradients >75 mm Hg) should also be treated, with a view to halting further disease progression. Medical therapies, other than amiodarone, have not been documented to affect the risk of sudden death [7 •• ] . Beta blockers continue to be at the frontline of medical therapies for children with HCM. They are useful for provocable left ventricular outflow tract obstruction occurring with exercise, but have not been documented to have any role in the amelioration of resting left ventricular outflow tract obstruction. Disopyramide, either alone or in combination with a b-blocker, has been shown to be useful in amelioration of resting or provocable left ventricular outflow tract obstruction or associated symptoms. Verapamil is best reserved for patients who do not have significant symptoms in the presence of left ventricular outflow tract obstruction as death has been reported to occur in this population receiving a calcium channel blocker.
Surgical
Surgical myectomy continues to be the standard of therapy for children with important symptoms in the presence of left ventricular outflow tract obstruction who are refractory to medical therapy. In experienced centers, the operative mortality is low and the procedure provides long-term relief of obstruction [7 •• ] . Isolated surgical myectomy will not benefit those children with associated abnormalities of the mitral subvalvular apparatus, which can also be a source of obstruction. In these patients, resection of anomalous chordae or surgical relief of papillary muscle fusion in association with an extended septal myectomy has been reported to provide good surgical results and avoid the need for mitral valve replacement 
Percutaneous alcohol septal ablation
This procedure involves the introduction of absolute alcohol into a target septal perforator branch of the left anterior descending coronary artery for the purpose of producing a myocardial infarction within the proximal ventricular septum. Septal hypokinesis and more remote remodeling occur, thereby relieving left ventricular outflow tract obstruction. While the procedure has been successful in providing intermediate-term resolution of outflow tract obstruction and associated symptoms in adults with HCM, the risks are not minimal and include heart block [23], ventricular septal rupture [24] , and death [23] . The procedure has yet to be subjected to the scrutiny of randomized controlled studies or long-term follow-up [7 •• ]. One of the major concerns regarding alcohol septal ablation relevant to the child or young adult with symptomatic obstructive HCM is the potential long-term risk for arrhythmia-related cardiac events, including sudden cardiac death, arising from the procedure itself. The risk of such an event may well outweigh the risk of sudden cardiac death from the disease itself and, for this and other reasons, there is no role for alcohol ablation in the treatment of children and adolescents [7 •• ] .
Conclusion
The diagnosis of HCM in children and adolescents is important, as there is a risk of both symptoms and sudden death. However, earlier diagnosis also leads to earlier onset of surveillance and management, which for these children must continue over the lifetime. The potential impact on long-term quality of life is great. Advances in the precision and utility of noninvasive assessment are important, as well as the development and evaluation of safe and effective therapies aimed at slowing the progression of the disease process, alleviating symptoms and lowering the risk of sudden life-threatening events.
